EU gives go-ahead for Roche's Perjeta with further 2013 approvals to follow
This article was originally published in Scrip
Roche said it anticipates further approvals this year for its targeted breast cancer drug Perjeta (pertuzumab), having secured EU approval for the product to be used in patients with previously untreated HER2-positive metastatic breast cancer (mBC).
You may also be interested in...
Outdated System Preventing Breast Cancer Patients Getting Access To Early Treatment In England, Says Roche
Roche Pharma AG has been scorned once again by the England's health technology appraisal body NICE – with the pricing group this time rejecting the big pharma's breast cancer treatment Perjeta (pertuzumab) for regular use on the NHS as a neoadjuvant therapy.
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.